ANTX AN2 Therapeutics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of AN2 Bio (ANTX)

The EV/Sales valuation demonstrates historical business value ranges, with the metric currently fixed at 0.00. The financial stability of AN2 Therapeutics, Inc. (ANTX) is based on substantial grants and liquid assets without credit encumbrances. Global growth potential is driven by the scaling of unique formulas at a low cost of production. Innovations are implemented through robotic molecule screening and automated research data analysis.

ANTX: AN2 Therapeutics Inc Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

ANTX (AN2 Therapeutics Inc): analytical breakdowns and indicator data

- market price and analyst price targets:
- company stock capitalization data:
- money and cash flow information:
Initial company analysis:AN2 Therapeutics, Inc.
Mass-produced product of AN2 Therapeutics

This ratio determines the market value of the business, including net debt, per unit of revenue, eliminating the impact of capital structure on the valuation. By analyzing changes in the EV/Sales multiple, an investor can see how the market values the potential for developing antibiotics against rare pulmonary infections relative to the current revenues of AN2 Therapeutics (ANTX) against the backdrop of clinical trial costs.